David Paez-Espino
Co-Founder & Chief Technology Officer Ancilia Biosciences
David Paez-Espino, PhD, is the Co-Founder and Chief Technology Officer of Ancilia Biosciences, a company developing CRISPR-based antivirals for microbiome health. Previously, he served as Associate Director at Mammoth Biosciences and completed postdoctoral research at UC Berkeley and the Joint Genome Institute. David is recognized for his expertise in CRISPR systems, virome research, and microbial genomics, with over 20 scientific publications and 30+ patents. At Ancilia, he leads technology development to harness CRISPR for precision microbiome modulation, advancing novel therapeutic strategies for infectious and chronic diseases.
Seminars
Thursday 29th January 2026
Reprogramming the Microbiome: Engineering Phage-Resistant LBPs for Durable Therapeutic Impact
11:30 am
- Demonstrate how CRISPR-enhanced bacterial strains resist phage attack to improve engraftment and therapeutic persistence
- Leverage virome analysis to uncover viral drivers of LBP failure across women’s health and gut indications
- Expand platform applications from vaginal microbiome to gut disorders, showcasing data from preclinical developments
